Release date: 2017-10-17 The medical health industry trend report (hereinafter referred to as “Reportâ€) released by CBinsights, a venture capital data website, proposes that medical equipment will present three major trends in the future: the first major trend is that 3D bio-printing technology makes organ transplantation more convenient and efficient; The megatrend is implantable device-assisted neurosurgical treatment; the third major trend is the growing range of applications for mobile small diagnostic devices. 3D bio-printing technology makes organ transplantation more convenient and efficient Organ transplantation has always been expensive and inefficient. Among them, heart and intestinal related organ transplantation is the most expensive. The advent of 3D bio-printing technology makes organ transplants worldwide more convenient and efficient. The number of various organ transplants in the United States each year and the average price spent Organs wait an average of more than a year San Francisco-based Prellis Biologic has used 3D printing technology to create microvessels and tissues. The company is currently investigating the use of 3D to print insulin-secreting cells in the pancreas and has begun to develop prints of immune-responsive and antibody-producing lymphoid organs. 3D printing company Biobot develops hardware, software, and reagents for the manufacture of living tissue. The company's flagship product is the Biobot2, which is accurate to sub-micron. This product is mainly practical and economical, each sold for only 40,000 US dollars; the product is small and can be placed on the desktop. A hardware product from Biobot Aspect Biosystems, a Canadian biotechnology company, develops custom hardware and software for 3D organizations. The company's core technology is Lab-on-a-Printers. The company has partnered with Johnson & Johnson to develop bioprinters for meniscus. A hardware product from Aspect Biosystems Implantable device assisted neurosurgical treatment For a long time, the development of medicine has been limited because it cannot interact well with the nervous system. In the past, medical understanding of anatomical neurology was lacking, and a neurological monitoring system that recorded brain activity was lacking, leading to the inability to link specific diseases to certain parts of the brain. Nowadays, medicine has a general understanding of anatomical neurology but is unclear about certain details, but it has been able to identify certain areas of the brain and use some auxiliary equipment for treatment, which is equivalent to the nervous system beginning to be extended beyond the body. The report believes that the two-way communication between the brain and the machine will become a routine; in the treatment of nervous system diseases (such as epilepsy), some software may replace drugs; computers will become the extension of human thinking. With the ambition to help the development of artificial intelligence, multi-millionaire Bryan Johnson founded Kernel. Using research from New York University, MIT, Columbia University, and Northwestern University, the company developed its own software and hardware for treating neurological diseases such as epilepsy, dementia, and Alzheimer's disease. Kernel also plans to initiate clinical trials using implantable neuronal devices similar to those shown to test whether the device can restore or improve memory function in mice. Kernel has now received $100 million in financing. G-Therapeutics, based in G-Therapeutics, has developed an implantable spinal cord assist device to help patients with spinal cord damage. The complete treatment plan includes both implantable spinal cord assistive devices and physical exercise. G-Therapeutics is currently conducting clinical trials to evaluate the efficacy of this device in patients with chronic incomplete spinal cord injury. Synchron is developing an implantable device called the Stentrode system to help paralyzed patients achieve direct brain control of mobile assistive devices. The Stentrode system is a small device that is positioned in the brain through intracranial blood vessels to identify electrical signals released by neurons. The company is embarking on an early clinical trial to test the safety and feasibility of the device. Mobile small diagnostic equipment is getting bigger and bigger The report shows that millions of patients have not been treated for lack of inexpensive mobile diagnostic techniques. Vinod Khosla, founder of Khosla Ventures, said: "Due to the development of software, diagnosis is becoming more and more convenient and has a larger application." QuantuMDx has developed a portable molecular diagnostic device. The company's flagship product, Q-POC, provides DNA sequencing for patient diagnostics and drug allergy testing and can be completed in 10-20 minutes. QuantuMDx is researching and developing applications that can test warfarin metabolism, sexually transmitted infections, and malaria. It also works with the Bill and Melinda Gates Foundation to test for tuberculosis and cervical cancer. This diagnostic device is expected to be commercialized by 2018. The handheld test system developed by Two-poreGuys' (2PG), based in Santa Cruz, Calif., works like a blood glucose monitor, but its one-time detector detects almost all molecules and has a pole. High sensitivity. The system became the first system used in liquid biopsies to examine colorectal cancer and pancreatic cancer. Testing in traditional laboratories is equally applicable to the 2PG platform, which offers unlimited possibilities for developing more test systems. In 2017, 2PG became the first company to apply a handheld detection system to liquid biopsy for colorectal cancer and pancreatic cancer. Basli LeafTechnologies is the winner of the 2017 Qualcomm Recorder X PRIZE competition. Based on an AI product called DxtER, the company has developed a handheld inspection device. Their main product is a non-invasive monitor for blood sugar, white blood cells and hemoglobin. The device is currently in Phase I clinical trials. The company is developing a digital receiver to perform an auxiliary examination of pneumonia and asthma. Source: health point healthpoint (micro signal caixin-life) Yancheng Rongtai Labware Co.,Ltd , https://www.shtestlab.com